Financial Performance - Revenue for 2023 reached 10,058,497,338.92 yuan, a 15.69% increase compared to 2022 [17] - Net profit attributable to shareholders was 2,797,351,515.70 yuan, up 13.15% year-on-year [17] - Total assets increased by 16.96% to 17,080,413,435.81 yuan at the end of 2023 [17] - Basic earnings per share (EPS) rose by 13.17% to 4.64 yuan [18] - Weighted average return on equity (ROE) decreased by 0.86 percentage points to 22.64% [18] - Operating cash flow decreased by 67.89% to 2,206,631,519.26 yuan due to changes in cash flow classification for fixed deposits [18] - Revenue for Q1 2023 was 262,951.76 million RMB, Q2 was 241,575.81 million RMB, Q3 was 255,460.11 million RMB, and Q4 was 245,862.05 million RMB [20] - Net profit attributable to shareholders in Q1 2023 was 76,968.13 million RMB, Q2 was 77,115.58 million RMB, Q3 was 86,381.14 million RMB, and Q4 was 39,270.30 million RMB [20] - Net cash flow from operating activities in Q1 2023 was 63,442.40 million RMB, Q2 was 73,418.57 million RMB, Q3 was 101,092.54 million RMB, and Q4 was -17,290.36 million RMB [20] - Non-recurring gains and losses for 2023 totaled -56,481,951.15 RMB, compared to -3,699,079.34 RMB in 2022 and 25,513,113.39 RMB in 2021 [23] - Government subsidies in 2023 amounted to 12,430,716.63 RMB, compared to 13,965,561.85 RMB in 2022 and 11,141,407.57 RMB in 2021 [22] - Total revenue for 2023 reached 10.06 billion yuan, a year-on-year increase of 15.69% [46] - Net profit for 2023 was 2.85 billion yuan, up 13.01% year-on-year [46] - Sales expenses increased by 61.95% to 782.78 million yuan, mainly due to increased promotion and advertising costs [47][49] - Other income surged by 97.72% to 21.52 million yuan, driven by VAT deduction policies [49] - Investment income rose by 67.78% to 126.19 million yuan, primarily due to increased interest income from time deposits [49] - The company's total assets stood at 17.08 billion yuan as of December 31, 2023 [46] - Operating cash flow decreased by 67.89% to 2.21 billion yuan, mainly due to changes in the classification of time deposits [49] - Total revenue for 2023 reached 1,003,618.59 million yuan, with a year-on-year increase of 15.70% [52][54] - The pharmaceutical manufacturing sector contributed 480,165.72 million yuan in revenue, a decrease of 75.77% compared to the previous year [52][54] - The pharmaceutical distribution sector generated 420,482.22 million yuan in revenue, with a year-on-year increase of 3.60% [52][54] - The cosmetics industry reported revenue of 70,675.80 million yuan, with a year-on-year increase of 62.18% [52][54] - Gross profit margin for the pharmaceutical distribution sector increased by 1.63 percentage points to 46.86% [52][54] - Online sales revenue was 73,000.11 million yuan, with a gross profit margin increase of 3.13 percentage points to 19.97% [55] - Offline sales revenue reached 930,618.48 million yuan, with a gross profit margin increase of 0.32 percentage points to 48.92% [55] - Production volume of liver disease drugs increased by 4.24% to 401.72 million boxes, while sales volume increased by 34.02% to 453.45 million boxes [56] - Direct material costs for liver disease drugs increased by 39.86% to 89,021.43 million yuan, accounting for 94.02% of total costs [57] - The total cost for pharmaceutical manufacturing increased by 43.30% to 116,353.40 million yuan, with direct material costs accounting for 92.76% [58] - Top 5 customers contributed sales of 883.46 million yuan, accounting for 8.80% of total annual sales [60] - Top 5 suppliers accounted for 1.21 billion yuan in procurement, representing 19.88% of total annual procurement [61] - Sales expenses increased by 61.95% to 782.78 million yuan, mainly due to increased promotion and advertising expenses [65] - Management expenses rose by 10.87% to 367.05 million yuan, primarily due to increased employee compensation and depreciation [66] - R&D investment totaled 232.35 million yuan, accounting for 2.31% of operating revenue [67] - The company has 237 R&D personnel, representing 8.50% of total employees [68] - Operating cash flow decreased by 4.67 billion yuan to 2.21 billion yuan, mainly due to changes in the classification of fixed deposits [71] - Investment cash flow improved by 3.53 billion yuan to -2.77 billion yuan, reflecting changes in fixed deposit classification [72] - Financing cash flow decreased by 193.48 million yuan to -769.30 million yuan, mainly due to reduced borrowing [72] - Cash and cash equivalents decreased by 53.58% to 11,587.46 million yuan, accounting for 6.78% of total assets [73] - Accounts receivable increased by 22.48% to 9,117.49 million yuan, accounting for 5.34% of total assets [73] - Inventory increased by 28.57% to 33,786.61 million yuan, accounting for 19.78% of total assets [73] - Other current assets increased by 45.56% to 91,442.74 million yuan, accounting for 53.54% of total assets [73] - Long-term equity investments decreased by 20.81% to 1,935.54 million yuan, accounting for 1.13% of total assets [73] - Construction in progress increased by 158.62% to 1,571.90 million yuan, accounting for 0.92% of total assets [73] - Retained earnings increased by 21.82% to 99,957.72 million yuan, accounting for 58.52% of total assets [74] - Overseas assets amounted to 518.35 million yuan, accounting for 0.30% of total assets [77] - Restricted assets totaled 1,071.76 million yuan, including 815.56 million yuan in cash and 256.19 million yuan in intangible assets [78] - The company's financial assets measured at fair value had a total impact of 21,720,121.28 RMB on current profits [25] - The company's financial assets measured at fair value totaled 4.91 billion yuan at the end of the period, with a net impact on other comprehensive income of 1.61 million yuan and a net impact on current profit of 21.72 million yuan [103] - The company's equity investments in listed companies, including Huarun Double-Crane, Liaoning Chengda, Industrial Securities, and Industrial Bank, had a total initial investment cost of 2.82 billion yuan and a total fair value of 3.66 billion yuan at the end of the period [104] - The total book value of private equity investments at the end of the period was RMB 1.2003 billion, with a net decrease of RMB 472.291 million during the period [105] - Xiamen Pien Tze Huang Hongren Pharmaceutical Co., Ltd. (consolidated) reported revenue of RMB 3.444 billion and net profit of RMB 1.1015 million [106] - Fujian Tongchun Pharmaceutical Co., Ltd. reported revenue of RMB 4.304 billion and net profit of RMB 53.6449 million [107] - The company distributed a cash dividend of 754,146,512.50 yuan (tax included) for 2022, accounting for 30.50% of the net profit attributable to shareholders [154] - The proposed cash dividend for 2023 is 1,399,695,927.20 yuan (tax included), representing 50.04% of the net profit attributable to shareholders [154][157] - The company did not propose any stock dividends or capital reserve to share capital conversion for 2023 [154][157] - The company's cash dividend policy ensures a minimum cash dividend ratio of not less than 30% of the distributable profit for the year, with adjustments requiring approval by two-thirds of the shareholders present at the general meeting [153] Research and Development - The company conducted 11 clinical studies on the secondary development of its core product, Pien Tze Huang, and completed 3 clinical studies [27] - The company completed 10 research projects on the pharmacological and toxicological effects of Pien Tze Huang, including its mechanism of action on bile acid metabolism and liver protection [27] - The company published 25 new research papers during the reporting period [27] - The company published a research paper on inhibiting colorectal cancer by regulating gut microbiota and metabolites in the top gastroenterology journal Gastroenterology (IF 29.4), enhancing product competitiveness [28] - 3 chemical drug Class 1 new drugs, 3 traditional Chinese medicine (TCM) Class 1.1 new drugs, and 1 TCM Class 1.2 new drug entered clinical research stage [28] - Obtained Phase II clinical trial summary report for Wandan Tablets, confirming clinical efficacy for mild to moderate generalized anxiety disorder [28] - Completed Phase I clinical research report for PZH2108 tablets, showing good safety and tolerability in Chinese healthy subjects [28] - Completed preclinical research for 2 chemical innovative drugs [28] - Newly authorized 26 invention patents and 4 utility model patents, transferred 2 invention patents [28] - Obtained 5 computer software copyright registration certificates and 2 non-major crop variety certification certificates [28] - 4 products including Compound Pien Tze Huang Ointment passed national patent-intensive product filing [28] - Passed the 2023 national intellectual property demonstration enterprise assessment and Fujian provincial intellectual property advantage enterprise review [28] - The company is focusing on secondary development of its core product Pien Tze Huang, as well as the development of new traditional Chinese medicine, classical formulas, and chemical drugs [85] - Key R&D projects include PZH2113 for tumors, PZH1215 for diabetic nephropathy, and PZH2114 for liver diseases, with various stages ranging from pre-clinical research to Phase II clinical trials [86] - The company has submitted applications for drug re-registration for Qinghuo Tablets and Sangju Ganmao Tablets, which are used for clearing heat and detoxifying, and treating wind-heat colds respectively [87] - R&D investment in 2023 was RMB 23,235.43 million, accounting for 2.31% of operating revenue [90] - The company's R&D investment accounted for 1.67% of net assets, with a capitalisation ratio of 0.00% [90] - The average R&D investment of peer companies was RMB 35,155.55 million [90] - Key R&D projects include modern disease spectrum research with an investment of RMB 7,691.41 million, a 17.88% increase year-on-year [92] - The company's R&D policy distinguishes between research and development phases, with development phase expenditures capitalised under specific conditions [88] Product Sales and Marketing - Sales of Pien Tze Huang capsules increased significantly during the reporting period, with Pien Tze Huang lozenges ranking first in sales in the liver and gallbladder medication category on Tmall and JD platforms [32] - Three major products, Angong Niuhuang Wan, Pien Tze Huang lozenges, and Ganbao, each achieved sales exceeding 100 million yuan [32] - The sales of Queen Brand Pien Tze Huang Pearl Cream exceeded 100 million yuan, and sales of five proprietary "Blue Hat" health food products doubled [32] - The company conducted over 4,500 offline terminal promotion activities and approximately 1,500 public welfare-themed activities, benefiting tens of thousands of people [33] - The company upgraded all "Pien Tze Huang Experience Halls" to "Pien Tze Huang Traditional Medicine Halls" starting January 3, 2024, to enhance brand image [45] - The company's terminal stores now cover over 100,000 locations through partnerships with major pharmacy chains [45] - The company's brand value was 40.94 billion yuan, ranking second among "China Time-Honored Brands" [43] - The company's sales model includes strategic partnerships with major pharmacy chains and the establishment of "Pien Tze Huang Traditional Medicine Halls" both domestically and internationally [93] - Business promotion expenses increased by 298.82 million yuan, with the parent company contributing an increase of 265.27 million yuan, Fujian Pien Tze Huang Cosmetics Co., Ltd. adding 40.24 million yuan, and Fujian Pien Tze Huang Health Food Co., Ltd. increasing by 13.49 million yuan, while Fujian Pien Tze Huang E-commerce Co., Ltd. decreased by 9.69 million yuan [98] - Advertising expenses decreased by 15.64 million yuan, with the parent company reducing expenses by 13.59 million yuan [99] - Operating expenses through e-commerce platforms decreased by 6.74 million yuan [99] - The company's sales expenses in 2023 were 783 million yuan, with a sales expense ratio of 7.78%, significantly lower than the industry average of 23.99 billion yuan and 44.33% [99] - Promotion, business promotion, and advertising expenses accounted for 67.90% of total sales expenses [94] - The company's main sales channels include domestic pharmacy sales, hospital sales, and overseas distribution [93] Corporate Governance and Leadership - The company held 2 shareholder meetings in the reporting period, addressing issues such as board reports, profit distribution, and financial budgets [118] - The company's board of directors held 7 meetings and 10 specialized committee meetings, with independent directors actively fulfilling their duties and providing professional opinions [119] - The company's board of directors revised the "Board Strategic Committee Work Rules" to enhance ESG governance and sustainability performance [119] - The company held two shareholders' meetings during the reporting period, with all proposals passed [123] - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period was 6.0237 million yuan [125] - The chairman of the board, Lin Zhihui, received a pre-tax remuneration of 234,800 yuan [124] - The general manager, Huang Jinming, received a pre-tax remuneration of 563,500 yuan [124] - The total pre-tax remuneration for independent directors during the reporting period was 240,000 yuan [124] - The total pre-tax remuneration for supervisors during the reporting period was 1.8012 million yuan [124] - The total pre-tax remuneration for senior management during the reporting period was 2.0237 million yuan [125] - The company's financial report for 2022 and financial budget for 2023 were approved at the 2022 annual shareholders' meeting [123] - The company's profit distribution plan for 2022 was approved at the 2022 annual shareholders' meeting [123] - The company's proposal to appoint additional directors was approved at the 2023 first extraordinary shareholders' meeting [123] - Lin Zhihui was appointed as the company's Party Committee Secretary and Chairman in August 2023 [126] - Huang Jinming has been serving as the company's Deputy Party Committee Secretary, Director, and General Manager since July 2019 [126] - Lai Wenning has been serving as the company's Director since December 2022 [126] - Yang Haipeng has been serving as the company's Director and Chief Accountant since January 2022 [126] - Fan Zhipeng has been serving as the company's Independent Director since March 2018 [126] - Du Shouying, born in December 1960, holds a Ph.D. in Clinical Chinese Medicine from Beijing University of Chinese Medicine and serves as an independent director for Hunan Fangsheng Pharmaceutical Co., Ltd. and Chongqing Huasen Pharmaceutical Co., Ltd. [127] - Zhang Lei, born in October 1985, is a Certified Public Accountant and currently serves as the director of the Shenzhen branch of Tianzhi International Accounting Firm (Special General Partnership). [127] - Chen Lei, born in January 1981, holds a Ph.D. in Finance and is currently a professor and vice dean at the School of Finance and Economics, Jimei University, and also serves as an independent director for Ruida Fund Management Co., Ltd. [127] - Xu Shibin, born in May 1972, has extensive experience in government and corporate roles, currently serving as the Deputy Party Secretary and Chairman of the Supervisory Board of the company. [127] - Huang Yalong, born in December 1965, is a senior accountant with a long history in the company's financial department, currently serving as the Director of the Audit Department and a staff supervisor. [127] - Wei Tengyun, born in February 1972, is a licensed pharmacist and engineer, currently serving as the Director of the First Workshop and a staff supervisor at the company. [127] - Chen Yuhong has been serving as the company's supervisor and director of the Enterprise Management Department since June 2022 [128] - Huang Qiumin has been serving as the company's supervisor and director of the Securities Investment Department since June 2022, and also as the chairman of Zhangzhou Pien Tze Huang Investment Management Co., Ltd [128] - Hong Fei has been serving as the company's vice president since August 2022 [128] - Chen Honghui has been serving as the company's vice president and board secretary since August 2022 [128] - Zhang Zexiu has been serving as the company's vice president and chairman of Fujian Pien Tze Huang Health Food Co., Ltd since January 2024 [128] - Lai Wenning has been serving as a director and vice president of Zhangzhou Jiulongjiang Group Co., Ltd since April 2022 [129] - Fan Zhipeng serves as a partner at Beijing Danggui Yuanz

2024年第一季度报告 证券代码：600436 证券简称：片仔癀 漳州片仔癀药业股份有限公司 2024 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

证券代码：600436 证券简称：片仔癀 公告编号：2024-021 漳州片仔癀药业股份有限公司 2024年第一季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第3号——行业信息披 露》（2022年修订）《上市公司行业信息披露指引第六号——医药制造》 （2022年修订）等相关法律法规，漳州片仔癀药业股份有限公司（以下 简称"公司"）现将2024年第一季度主要经营数据披露如下： 一、 公司 2024 年第一季度主营业务分行业情况 单位：万元 人民币 | 行业 | 主营业务 | 主营业务 | 毛利率 | 主营业务 收入增长 | 主营业务 成本增长 | 毛利率 | | --- | --- | --- | --- | --- | --- | --- | | | 收入 | 成本 | （%） | 率（%） | 率（%） | 增减情况 | | 医药 | 165,374.40 | 48,820.37 | 70.48 | 25.94 | 57.03 | 减少5.84个 | | 制造业 ...

漳州片仔癢药业股份有限公司 内部控制审计报告 华兴审字[2024]23012960030 号 华兴会计师事务所(特殊普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查 兴会计师事务所(特殊普通合 IG CERTIFIED PUBLIC ACCOUNT 52 Hudong Road. Fuzhou. Fujian. China Http://www.fihxcpa.com 内部控制审计报告 华兴审字[2024]23012960030号 漳州片仔擴药业股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业标准的相关要求, 我们审计了漳州片仔擴药业股份有限公司(以下简称"片仔廣公司")2023年 12月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是 片仔擴公司董事会的责 ...

漳州片仔癀药业股份有限公司 2023 年度独立董事述职报告（李广培） 本人作为漳州片仔癀药业股份有限公司（以下简称"公 司"）第七届董事会独立董事，在 2023 年度本人任职期间严 格遵照《中华人民共和国公司法》《中华人民共和国证券法》 《中国证监会上市公司治理准则》《中国证监会上市公司独 立董事规则》等法律法规，以及《漳州片仔癀药业股份有限 公司章程》（以下简称"《公司章程》"）、《漳州片仔癀药业股 份有限公司独立董事工作制度》等规范性要求，谨遵忠实、 勤勉的原则，恪守独立董事履职规范，谨慎、独立、客观地 行使独立董事权利及义务。现将本人 2023 年度任职期间的 履职情况报告如下： 一、独立董事的基本情况 作为公司独立董事，本人拥有较丰富的企业管理专业知 识和经验，具备工商管理专业教授职称和技术经济及管理专 业博士学位，在从事的专业领域积累了丰富的经验。本人个 人工作履历、专业背景以及任职情况如下： 李广培，男，1968 年 3 月出生，管理学博士。1991 年 8 月至今，历任福州大学经济与管理学院助教、讲师、副教授、 教授、硕士生导师、系主任。兼任福建睿能科技股份有限公 司独立董事。2017 年 8 ...

漳州片仔癀药业股份有限公司 2023 年度董事会工作报告 各位董事、监事、高级管理人员： 大家好，现在我代表公司董事会，向各位汇报董事会 2023 年度工作情况和 2024 年度工作计划，请予以审议。 2023 年是全面贯彻落实党的二十大精神的开局之年，也是 "十四五"规划承上启下的关键之年。公司董事会坚持以习近 平新时代中国特色社会主义思想为指导，深入贯彻落实党的二 十大精神，在各位股东的有力支持下，围绕"守正创新、行稳 致远"发展理念，踔厉奋发，团结协作，带领全体干部员工齐 心协力，认真完成各项工作，有力推动片仔癀高质量发展。 一、 经营发展成果 （一）经营业绩再创新高：2023 年公司实现合并营业收入 1,005,849.73 万元，比增 15.69%；实现利润总额 336,891.25 万元，比增 13.14%；实现归母净利润 279,735.15 万元，比增 13.15%；实现上缴税收 119,186.72 万元；完成全年经营目标。 （二）企业荣誉硕果累累：公司被国务院国资委纳入"双 百企业"名单；入选国务院国资委"创建世界一流专业领军示 范企业"名单，为中药领域唯一获此殊荣的企业；上榜"中药 上市 ...

第一部分 2023年度财务决算 根据华兴会计师事务所（特殊普通合伙）出具的审计 报告，审定2023年12月31日的资产总额170.80亿元（其 中：母公司134.15亿元），负债总额31.60亿元（其中：母 公司9.77亿元），股东权益总额139.20亿元（其中：母公 司124.38亿元），归属于母公司所有者权益133.76亿元， 少数股东权益5.44亿元。全年实现营业收入100.58亿元 （其中：母公司46.05亿元），利润总额33.69亿元（其 中：母公司29.49亿元），净利润28.51亿元（其中：母公 司25.28亿元），归属于母公司所有者的净利润27.97亿 元，每股收益4.64元，加权平均净资产收益率22.64%。经 营活动产生的现金流量净额22.07亿元（其中：母公司 18.97亿元）。年终财务决算综合反映了我公司合并后2023 年12月31日的财务状况及2023年度的经营成果和现金流 量。 | 序号 | 指标名称 | 2023 | 年度 | 2022 | 年度 | | --- | --- | --- | --- | --- | --- | | 1 | 每股收益(元) | | 4.64 | | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）根据《上市 公司独立董事管理办法（2023 年 8 月修订）》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作（2023 年 12 月修订）》《上 市公司章程指引（2023 年 12 月修订）》《上市公司监管指引第 3 号 ——上市公司现金分红（2023 年 12 月修订）》等相关法律法规的要 求，为进一步完善公司治理，结合公司发展实际，公司拟对《漳州 片仔癀药业股份有限公司章程》（以下简称"《公司章程》"）部分条 款进行修订，详见修订前后对比表。 证券代码：600436 证券简称：片仔癀 公告编号：2024-019 漳州片仔癀药业股份有限公司 关于修订《公司章程》的公告 此次修改的《公司章程》于 2024 年 4 月 18 日经第七届董事会 第十八次会议审议通过。该议案尚需提交至公司股东大会审议。 同时，董事会提请股东大会授权公司管理层办理工商变更登记 等相关事宜。上述变更内容以工商登记机关最终核准内容为准。 特此公告。 ...

漳州片仔癀药业股份有限公司 2023 年度审计委员会履职情况报告 各位董事、监事、高级管理人员： 根据《中国证监会上市公司治理准则》《上海证券交易所上 市公司自律监管指引第 1 号——规范运作》《漳州片仔癀药业股 份有限公司章程》（以下简称"《公司章程》"）、《漳州片仔癀药 业股份有限公司董事会审计委员会工作细则》等相关规定，作 为漳州片仔癀药业股份有限公司（以下简称"公司"）的审计委 员会委员，我们本着勤勉尽责的原则，对公司 2023 年度的相关 事项进行认真审核，积极发挥审计委员会的监督职能。现将 2023 年度审计委员会的履职情况汇报如下： 一、审计委员会基本情况 公司审计委员会现由独立董事张磊先生、独立董事杜守颖女 士及非执行董事赖文宁先生组成，其中张磊先生为主任委员。 2023 年 4 月，根据董事会的成员变化，公司第七届董事会第十 次会议调整非执行董事赖文宁先生为审计委员会成员。2023 年 8 月，因为原独立董事贾建军先生的任期届满，公司第七届董事 会第十三次会议新增独立董事张磊先生为审计委员会的主任委 员。 独立董事成员占审计委员会成员总数的 1/2 以上，独立董事 张磊先生具备较丰富的会计专 ...

漳州片仔癀药业股份有限公司 2023 年度独立董事述职报告（杜守颖） 2023 年度，本人作为漳州片仔癀药业股份有限公司（以 下简称"公司"）第七届董事会独立董事，严格遵照《中华 人民共和国公司法》《中华人民共和国证券法》《中国证监会 上市公司治理准则》《中国证监会上市公司独立董事规则》 等法律法规，以及《漳州片仔癀药业股份有限公司章程》（以 下简称"《公司章程》"）、《漳州片仔癀药业股份有限公司独 立董事工作制度》等规范性要求，谨遵忠实、勤勉的原则， 恪守独立董事履职规范，谨慎、独立、客观地行使独立董事 权利及义务。现将本人 2023 年度履职情况报告如下： 二、独立董事年度履职情况 在 2023 年度任职期间，本人积极出席公司的历次股东 大会、董事会和董事会各相关专门委员会，认真审议各项议 案，并根据相关规定发表独立意见，诚信勤勉，忠实尽责。 （一）出席董事会和股东大会会议的情况 报告期内，公司共召开股东大会 2 次，召开董事会 7 次， 本人亲自出席了公司的股东大会 1 次，董事会会议 7 次，就 公司股东大会、董事会审议的各项议案，忠实履行独立董事 职责。报告期内，本人未对公司董事会、股东大会审议通过 ...